Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd | ADX71149 (mGlu2 PAM) - (JNJ-40411813) | Epilepsy | Phase 2 | Trial Discontinued | oral | Neurology |
| Addex Therapeutics Ltd | Dipraglurant (mGlu5 NAM) | PD-LID, SUD, NDD, pain, poststroke/TBI rehabilitation | Phase 2 | Ongoing | Oral | Neurology |
| Adial Pharmaceuticals Inc | AD04 | Alcohol Use Disorder (AUD) in heavy drinking patients | Phase 2 | Trial Completed | oral | Anti-Addiction |
| Adial Pharmaceuticals Inc | AD04 - (ONWARD) | Alcohol use disorder | Phase 3 | Data Released | oral | Psychiatric |
| Adicet Bio Inc. | ADI-001 | Lupus nephritis and Systemic Lupus Erythematosus (SLE) | Phase 2 | Trial Planned | Intravenous | Immunology |
| Aditxt Inc. | Avigan Reeqonus Qifenda (favipiravir) - (PRESECO) | Covid-19 | Phase 3 | Oral | COVID-19 | |
| Adlai Nortye Ltd. | Palupiprant (AN0025) + Keytruda - (ARTEMIS) | TNBC, NSCLC, bladder cancer, microsatellite stable CRC and cervical cancer | Phase 2 | Ongoing | Oral | Oncology |
| Adlai Nortye Ltd. | Buparlisib (AN2025) + Paclitaxel - (BURAN) | Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) | Phase 3 | Enrollment Conclusion | Oral and intravenous | Oncology |
